Upgrade to SI Premium - Free Trial

Ultragenyx Pharma (RARE)

15.30 +0.45 (3.03%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/4/26)

Latest Headlines

Ultragenyx Pharma (RARE) PT Lowered to $19 at Goldman Sachs September 4, 2026 6:38 AM - StreetInsider Ultragenyx Pharma (RARE) PT Lowered to $32 at Barclays September 4, 2026 4:22 AM - StreetInsider Morgan Stanley Downgrades Ultragenyx Pharma (RARE) to Equalweight September 3, 2026 1:05 PM - StreetInsider Increasing unusual call volume: GPRO XP RARE CHPT WSC WOOF CBRL DPRO KHC BNTX SBLK TSLT CPB September 3, 2026 9:44 AM - StreetInsider BofA Securities Downgrades Ultragenyx Pharma (RARE) to Neutral September 3, 2026 9:40 AM - StreetInsider Ultragenyx Pharma (RARE) PT Lowered to $18 at TD Cowen September 3, 2026 8:05 AM - StreetInsider RBC Capital Downgrades Ultragenyx Pharma (RARE) to Sector Perform September 3, 2026 7:28 AM - StreetInsider Ultragenyx Pharma (RARE) PT Lowered to $25 at H.C. Wainwright September 3, 2026 6:54 AM - StreetInsider Ultragenyx Pharma (RARE) PT Lowered to $37 at Canaccord September 3, 2026 6:37 AM - StreetInsider Ultragenyx Pharma (RARE) PT Lowered to $33 at Cantor Fitzgerald September 3, 2026 6:35 AM - StreetInsider Premarket movers: Snowflake, Five Below surge after strong earnings September 3, 2026 6:32 AM - StreetInsider Ultragenyx Pharma (RARE) call put ratio 1 call to 3 puts into Phase 3 results September 3, 2026 6:01 AM - StreetInsider Ultragenyx Pharma (RARE) PT Lowered to $18 at Wells Fargo, Downgrades to Equalweight September 3, 2026 5:49 AM - StreetInsider JPMorgan Downgrades Ultragenyx Pharma (RARE) to Neutral September 3, 2026 4:10 AM - StreetInsider Baird Downgrades Ultragenyx Pharma (RARE) to Neutral September 3, 2026 4:09 AM - StreetInsider Evercore ISI Downgrades Ultragenyx Pharma (RARE) to In Line September 3, 2026 2:36 AM - StreetInsider Morgan Stanley Reiterates Overweight Rating on Belimo Holding AG (BEAN:SW) (BLHWF) September 3, 2026 2:35 AM - StreetInsider After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE September 2, 2026 4:26 PM - StreetInsider Ultragenyx Angelman syndrome drug fails Phase 3 trial endpoints September 2, 2026 4:01 PM - StreetInsider Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome September 2, 2026 4:01 PM - StreetInsider Ultragenyx publishes 96-week phase 3 data for GSDIa gene therapy September 1, 2026 4:06 PM - StreetInsider Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journ September 1, 2026 4:05 PM - StreetInsider Ultragenyx Pharma (RARE) PT Raised to $50 at Wells Fargo August 28, 2026 6:30 AM - StreetInsider Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) August 25, 2026 4:30 PM - StreetInsider Ultragenyx Pharma (RARE) PT Raised to $80 at JPMorgan August 25, 2026 8:28 AM - StreetInsider Ultragenyx Pharma (RARE) PT Raised to $74 at Morgan Stanley August 21, 2026 9:15 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on Ultragenyx Pharma (RARE) August 20, 2026 6:56 AM - StreetInsider Ultragenyx Pharma (RARE) PT Raised to $46 at Wells Fargo August 20, 2026 6:45 AM - StreetInsider Ultragenyx Pharma (RARE) PT Raised to $83 at Canaccord August 20, 2026 6:44 AM - StreetInsider Citi raises Ultragenyx price target to $58 after FDA approval August 20, 2026 5:04 AM - StreetInsider Form 8-K Ultragenyx Pharmaceutica For: Aug 19 August 19, 2026 5:25 PM - SEC Filing FDA grants accelerated approval to Ultragenyx gene therapy for GSDIa August 19, 2026 5:21 PM - StreetInsider Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa) August 19, 2026 5:21 PM - Globe NewsWire Form SCHEDULE 13G Ultragenyx Pharmaceutica Filed by: RTW INVESTMENTS, LP August 14, 2026 8:15 AM - SEC Filing Form SCHEDULE 13G Ultragenyx Pharmaceutica Filed by: AQR CAPITAL MANAGEMENT LLC August 13, 2026 9:21 AM - SEC Filing Tactical Resources completes Plum merger, set for Nasdaq debut August 13, 2026 6:01 AM - StreetInsider Tactical Resources Completes Business Combination with Plum Acquisition Corp. III and Prepares for Nasdaq Listing August 13, 2026 6:00 AM - BizWire Form 20-F Tactical Resources Corp. For: Aug 12 Filed by: Plum III Merger Corp. August 12, 2026 5:13 PM - SEC Filing Form 8-K Ultragenyx Pharmaceutica For: Aug 07 August 11, 2026 8:30 AM - SEC Filing H.C. Wainwright Reiterates Buy Rating on Ultragenyx Pharma (RARE) August 10, 2026 6:43 AM - StreetInsider Form SCHEDULE 13G Ultragenyx Pharmaceutica Filed by: STATE STREET CORP August 7, 2026 11:05 AM - SEC Filing Ultragenyx Pharma (RARE) PT Lowered to $45 at Wells Fargo August 5, 2026 7:57 AM - StreetInsider Form 10-Q Ultragenyx Pharmaceutica For: Jun 30 August 5, 2026 6:02 AM - SEC Filing Ultragenyx Pharma (RARE) Tops Q2 EPS by 32c ; Offers Guidance August 5, 2026 1:02 AM - StreetInsider Form 8-K Ultragenyx Pharmaceutica For: Aug 04 August 4, 2026 4:10 PM - SEC Filing Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update August 4, 2026 4:05 PM - StreetInsider Form 4 Ultragenyx Pharmaceutica For: Aug 03 Filed by: Parschauer Karah Herdman August 4, 2026 3:16 PM - SEC Filing Form 4 Ultragenyx Pharmaceutica For: Aug 03 Filed by: Horn Howard August 4, 2026 3:14 PM - SEC Filing Ultragenyx Pharma (RARE) PT Lowered to $35 at Guggenheim August 4, 2026 6:49 AM - StreetInsider Form 144 Ultragenyx Pharmaceutica Filed by: Horn Howard August 3, 2026 4:19 PM - SEC Filing Form SCHEDULE 13G/A Ultragenyx Pharmaceutica Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC July 31, 2026 11:40 AM - SEC Filing Form SCHEDULE 13G Ultragenyx Pharmaceutica Filed by: VANGUARD CAPITAL MANAGEMENT LLC July 31, 2026 10:46 AM - SEC Filing Form SCHEDULE 13G/A Ultragenyx Pharmaceutica Filed by: BlackRock, Inc. July 30, 2026 11:20 AM - SEC Filing Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update July 28, 2026 4:05 PM - Globe NewsWire Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) July 24, 2026 4:30 PM - StreetInsider Tactical Resources Announces Exchange Ratio for Business Combination with Plum Acquisition Corp. III July 22, 2026 8:30 AM - BizWire Ultragenyx Pharma (RARE) PT Raised to $77 at Jefferies July 20, 2026 5:37 PM - StreetInsider Tactical Resources and Plum Acquisition Corp. III Announce Receipt of Nasdaq Approval; Transaction Expected to Close on July 28, 2026 July 20, 2026 8:30 AM - BizWire Ultragenyx releases 2025 impact report on rare disease programs July 8, 2026 9:08 AM - StreetInsider Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact July 8, 2026 9:08 AM - Globe NewsWire Ultragenyx Pharma (RARE) PT Raised to $40 at RBC Capital July 7, 2026 7:59 AM - StreetInsider Form 4 Ultragenyx Pharmaceutica For: Jul 01 Filed by: Horn Howard July 6, 2026 3:37 PM - SEC Filing Form 144 Ultragenyx Pharmaceutica Filed by: Horn Howard July 1, 2026 4:19 PM - SEC Filing Calidi Biotherapeutics adds biopharma veteran Corsee Sanders to board June 23, 2026 8:00 AM - StreetInsider Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors June 23, 2026 8:00 AM - StreetInsider Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) June 19, 2026 4:30 PM - StreetInsider Form 4 Ultragenyx Pharmaceutica For: Jun 15 Filed by: Sanders Corazon (Corsee) D. June 15, 2026 6:51 PM - SEC Filing Form 4 Ultragenyx Pharmaceutica For: Jun 15 Filed by: Parschauer Karah Herdman June 15, 2026 6:46 PM - SEC Filing Form 144 Ultragenyx Pharmaceutica Filed by: Parschauer Karah Herdman June 15, 2026 4:51 PM - SEC Filing Form 144 Ultragenyx Pharmaceutica Filed by: Sanders Corazon (Corsee) D. June 15, 2026 4:12 PM - SEC Filing Form S-8 Ultragenyx Pharmaceutica June 12, 2026 1:40 PM - SEC Filing Full Article List